Stay in the know
We’ll send you the latest insights and briefings tailored to your needs
Leading global law firm Herbert Smith Freehills has advised Mitsui & Co., Ltd. on its strategic acquisition of a 10% interest in JSC R-Pharm, one of the largest pharmaceutical companies in Russia.
The investment will help R-Pharm contribute to the Russian government's policy to produce more and higher quality drugs domestically, with Mitsui helping R-Pharm to enhance its manufacturing technology and using its networks to accelerate R-Pharm's licensing of new drugs from Japanese, European and American manufacturers.
The firm advised Mitsui on all aspects of the transaction, including due diligence (including on IP rights, distribution arrangements and regulatory approvals), competition law, structuring, and transaction documents.
The team was led from Tokyo by partner Graeme Preston and senior associate James Hearne, and from Moscow by partner Oleg Konnov, senior associate Artjom Tamaev and associate Bogdana Shtoma.
"We're delighted to have assisted Mitsui again on such a strategic transaction," said Graeme. "Deals between Asia and Russia have increased greatly over the past three years, and we're now seeing activity increase between Tokyo and Moscow as well, following bilateral government initiatives to drive trade growth. This was a perfect transaction to showcase the seamless teamwork of our market-leading corporate M&A practices in Tokyo and Moscow."
Oleg said: "This is a major Russian-Japanese transaction in the pharma sector that hopefully will encourage more Japanese investments in Russian hi-tech projects where Japanese companies are particularly strong".
BACKGROUND
For further information on this article please contact
Sally Greig, Head of Communications, Asia
Hong Kong
We’ll send you the latest insights and briefings tailored to your needs